Acceptability limits based on biology goals in haematology EQAS

The clinical impact and molecular biolog

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy

✍ Kevin D. Boyd; Fiona M. Ross; William J. Tapper; Laura Chiecchio; GianPaolo Dagr 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 1 views

## Abstract Hemizygous deletion of 17p (del(17p)) has been identified as a variable associated with poor prognosis in myeloma, although its impact in the context of thalidomide therapy is not well described. The clinical outcome of 85 myeloma patients with del(17p) treated in a clinical trial incor